Mymetics, Baylor College of Medicine to develop COVID-19 vaccine
Mymetics Corp. entered into a research collaboration with Baylor College of Medicine and Texas Children's Center for Vaccine Development to create a potential vaccine against COVID-19.
Under the agreement, Baylor will assess its recombinant protein-based SARS-CoV and SARS-CoV-2 antigens and combine them with Mymetics BV's virosomes, a vaccine carrier, to create a suitable vaccine.
Swiss biotech Mymetics aims to test a virosome-based vaccine candidate in humans within 12 months, the company said in a May 18 news release. Mymetics and Baylor are seeking additional funding for the clinical trials.
As of May 18, there have been over 4.7 million confirmed cases of COVID-19 worldwide, with over 315,700 deaths, according to data from Johns Hopkins University's Center for Systems Science and Engineering.